The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Austin 512-520-0221 Corpus Christi 361-254-7873 San Antonio 210-874-2615 Nationwide Toll Free 866-517-5659
Contact us 24/7 Contact us 24/7

Our attorneys and staff continue to work through COVID-19 and remain available 24/7, ready to fight for you. Our video conferencing, case management, and telecommunications systems allow us to stay in constant contact with our clients and pursue their claims without interruption – all without our clients leaving the comfort of their homes. You focus on staying healthy and safe, we’re here to handle the rest.

Bardoxolone Clinical Trials

Bardoxolone Methyl Linked to Increased Risk of Death

In October 2012, an independent data monitoring committee ordered that Reata Pharmaceuitcals terminate a phase 3 clinical trial for their investigational drug bardoxolone methyl due to increased reports of major cardiovascular events and death. Reata is now pursuing new clinical research for the drug, despite these serious risks.


In the BEACON Trial, Reata was testing bardoxolone as a possible treatement for chronic kidney disease in patients diagnosed from type 2 diabetes mellitus. Unfortunately, clinical data indicates that these patients were put at an increased risk of suffering serious cardiovascular events and death.

According to clinical trial data:

  • 1,255 adverse events were reported by patients receiving bardoxolone.
  • 139 patients receiving bardoxolone suffered non-fatal heart attacks, non-fatal stoke, were hospitalized for heart failure, or died from cardiovascular causes.
  • 96 reports of heart failure were recorded in patients taking bardoxolone.

By the time the trial was terminated, 27 patients being treated with bardoxolone had died from cardiovascular causes, compared to 19 cardiovascular deaths recorded in the placebo group. To make matters worse, the New England Journal of Medicine concluded that bardoxolone was ineffective at preventing the progression of end stage renal failure, meaning patients receiving the drug had not benefited from their treatment.

Despite their previous trial being terminated for cardiovascular events, Reata is now recruiting patients for a clinical trial assessing bardoxolone’s effecicy as a potential treatment for pulmonary arterial hypertension – a leading cause of heart failure.


The following adverse events were reported in patients being treated with bardoxolone:

  • Muscle pain
  • Nausea
  • Edema
  • Upper and lower respiratory tract infection
  • Abnormal breathing
  • Diarrhea
  • Gastrointestinal symptoms
  • Renal failure
  • Heart failure


Contact Us for a FREE Case Review

866-517-5659 •

Do you really want to end conversation?
chat-icon Live chat
avatar Waiting